Menu

Div Gupta's practice focuses on the representation of public and private emerging growth companies and investment banking firms. He has handled a variety of significant business transactions, including public offerings of equity, high yield debt and convertible debt, venture capital financings and mergers and acquisitions. He also advises a number of private companies as well as public companies on securities and general corporate matters. Div is ranked in Legal 500 and Chambers USA for his work in Capital Markets, Life Sciences and Healthcare, and has been named by Law360 as a Rising Star in Capital Markets and recognized by Who's Who Legal as a leading life sciences lawyer. Div is consistently among the nation's leaders in IPOs and other capital markets transactions run year after year. Clients describe him as “collaborative, helpful and productive” noting that he is “very solutions-oriented” and “a pleasure to work with.”

Download full bio 

Experience

  • Karuna Therapeutics – $862.5 Million Follow-on Offering 

  • Silence Therapeutics – $56.5 Million Registered Direct Offering 

  • Cerevel Therapeutics – $253.8 Million Follow-on Offering and Concurrent $345.0 Million Rule 144A Convertible Notes Offering 

  • Verona Pharma – $150 Million Follow-on Offering 

  • Verve Therapeutics – $258.8 Million Follow-on Offering 

  • View all

Education

  • Harvard Law School
    JD, cum laude, 2000

  • Yale University
    BS, magna cum laude, Phi Beta Kappa, 1997


Admissions & Credentials

California

New York

Texas

Rankings & Accolades

    Chambers USA: Capital Markets - Nationwide (Eastern United States) (2020 – 2022)

    Chambers USA: Life Sciences: Corporate/Commercial - Nationwide (2022)

    Legal 500: Key Lawyer - Capital Markets: Equity Offerings and Healthcare: Life Sciences (2020 – 2021)

    Law 360 Rising Star (2015)

    Who's Who Legal: Life Sciences (2018)

"highly regarded for his experience assisting life sciences companies on IPOs and other capital markets matters"

"Divakar is excellent in supporting our company."

Chambers USA: Life Sciences: Corporate/Commercial - Nationwide (2022)